Business Context and Reporting Period
This Form 8-K covers events occurring on August 31, 2026, for BioXcel Therapeutics, Inc. (BTAI). The Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on August 27, 2026, in the United States Bankruptcy Court for the District of Delaware. This filing details the execution of a Debtor-in-Possession (DIP) financing agreement and the subsequent delisting of the Company's common stock from The Nasdaq Capital Market.
Key Financial Metrics and Obligations
The filing does not provide historical revenue, profit, or cash flow metrics. The primary financial data relates to the new DIP Facility:
- Total DIP Facility Size: Up to $77.25 million in aggregate principal.
- New Money Loans: Up to $19 million (initial draw of $9.5 million available immediately).
- Roll-Up Loans: Up to $58.25 million (conversion of prepetition obligations).
- Interest Rate: 13.00% per annum (cash interest on New Money; interest on Roll-Up Loans is payable in kind).
- Exit Fee: 4.0% of the aggregate principal amount upon repayment.
- Maturity Date: January 27, 2027.
- Liquidity Covenant: Maintenance of a minimum liquidity amount of $250,000.
Material Changes
Significant material changes include:
- Bankruptcy Status: The Company is now operating under Chapter 11 protection.
- Capital Structure: Creation of a super-priority senior secured priming lien on substantially all assets in favor of the DIP Lenders (affiliates of Oaktree Capital Management and Qatar Investment Authority).
- Stock Listing: Nasdaq has determined to delist the Company's common stock due to the Chapter 11 filing. Trading is suspended effective September 8, 2026.
- Trading Venue: The stock is expected to trade on the Pink Limited Market (OTC), which may result in reduced liquidity and lower trading prices.
Outlook, Risks, and Management Commentary
Management expects to receive the initial $9.5 million draw and roll up $29.75 million in prepetition obligations on September 1, 2026. Proceeds will fund working capital, case administration costs, and professional fees. The Company does not intend to appeal the Nasdaq delisting.
Key Risks and Contingencies:
- Ability to obtain timely Court approval for motions and the final DIP order.
- Compliance with the 13-week budget and case milestones.
- Potential disruption to relationships with suppliers, vendors, and employees.
- Increased administrative and legal costs associated with the bankruptcy process.
- Uncertainty regarding the ability to consummate a transaction or reorganization plan.
Investor Verification Checklist
- Confirm the status of the Final DIP Order and the full $77.25 million facility approval.
- Monitor the transition of stock trading from Nasdaq to the Pink Limited Market and associated liquidity impacts.
- Review the approved 13-week budget and compliance with the $250,000 minimum liquidity covenant.
- Assess the timeline for the Chapter 11 reorganization plan or potential asset sale under Section 363.
- Verify the treatment of existing prepetition debt holders versus the new super-priority DIP lenders.